Foghorn Therapeutics Provides Third Quarter 2021 Corporate Update
November 09, 2021 07:00 ET
|
Foghorn Therapeutics
-- First patient dosed in phase 1 clinical trial of FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma --...
Foghorn Therapeutics Announces Presentation at Upcoming 4th Annual Targeted Protein Degradation Summit
October 19, 2021 16:05 ET
|
Foghorn Therapeutics
CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...